Ocular Therapeutix Inc
Change company Symbol lookup
Select an option...
OCUL Ocular Therapeutix Inc
BVNNF Bevcanna Enterprises Inc
GOOG Alphabet Inc
BAC Bank of America Corp
ED Consolidated Edison Inc
FRAN Francesca's Holdings Corp
CWBHF Charlotte's Web Holdings Inc
SALM Salem Media Group Inc
ASML ASML Holding NV
FUN Cedar Fair LP
Go

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Closing Price
$9.24
Day's Change
0.39 (4.41%)
Bid
--
Ask
--
B/A Size
--
Day's High
9.38
Day's Low
8.86
Volume
(Heavy Day)
Volume:
1,993,397

10-day average volume:
907,266
1,993,397

Ocular Therapeutix(TM) to Present at Two Upcoming Investor Conferences

7:00 am ET September 3, 2020 (BusinessWire) Print

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present and host investor meetings at the following conferences:

2020 Wells Fargo Virtual Healthcare Conference Date: Thursday, September 10, 2020 Analyst-hosted fireside chat: 4:00 PM ET

H.C. Wainwright 22nd Annual Global Investment Conference Date: Monday, September 14, 2020 Presentation Time: 1:30 PM ET

A live webcast of the presentations can be accessed by visiting the Investors section of the Company's website at investors.ocutx.com.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix's first commercial drug product, DEXTENZA, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix recently completed a Phase 3 clinical trial evaluating DEXTENZA for the treatment of ocular itching associated with allergic conjunctivitis. The Company's earlier stage development assets currently in Phase 1 trials include OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension, OTX-CSI (cyclosporine intracanalicular insert) for the treatment of the signs and symptoms of dry eye disease and OTX-TKI (axitinib intravitreal implant) for the treatment of retinal diseases. Also, Ocular Therapeutix is currently developing OTX-DED (dexamethasone intracanalicular insert) for the treatment of episodic dry eye and, in collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal injection) for an extended-delivery formulation of aflibercept for the treatment of retinal diseases. Ocular Therapeutix's first product, ReSure(R) Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200903005193/en/

SOURCE: Ocular Therapeutix, Inc.">

Investors 
Ocular Therapeutix
Donald Notman
Chief Financial Officer
dnotman@ocutx.com


or


Westwicke, an ICR Company
Chris Brinzey, 339-970-2843
chris.brinzey@westwicke.com


Media 
Ocular Therapeutix
Scott Corning
Senior Vice President, Commercial
scorning@ocutx.com
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.